Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study With Pacritinib to Inhibit JAK/STAT Signaling in Refractory Colorectal Cancer

NCT02277093 is registered in ClinicalTrials.gov with Washington University School of Medicine as lead sponsor.

NCT NCT02277093
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02277093 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study With Pacritinib to Inhibit JAK/STAT Signaling in Refractory Colorectal Cancer
Lead sponsor
Washington University School of Medicine
Phase
Phase 2
Overall status
Terminated
Start date
September 22, 2015
Completion date
October 27, 2016
Enrollment
11 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer